Tumor stroma ingredient in colorectal cancer: Current status and perspectives

doi:10.3877/cma.j.issn.2095-3224.2020.05.003

Abstract

Abstract:

Colorectal cancer (CRC) is one of the most common gastrointestinal malignant tumors worldwide, and its incidence is increasing year by year. Studies have shown that tumor stroma plays an active role in the occurrence and development of tumors. Tumor stroma, through the interaction with tumor essence ingredient, it affects the progression of CRC and the ability of tumor metastasis it promotes the occurrence, development and metastasis of CRC. Therefore, it is very important to explore the specific role, molecular mechanism and mechanism of tumor stroma components in the progression of CRC clinical application is essential. This article reviews the current research progress of tumor stroma in CRC at home and abroad.

Key words: Colorectal neoplasms, Tumor stroma, Tumor-infiltrating lymphocytes, Tumor-associated macrophages, Cancer-associated fibroblasts, Tumor budding

Tengfei Li, Chen Huang. Tumor stroma ingredient in colorectal cancer: Current status and perspectives[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(05): 447-452.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.05.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I05/447

Figures/Tables 2

References 34

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA: A Cancer Journal for Clinicians, 2020, 70: 7-30.
[2]	郑荣寿，孙可欣，张思维，等. 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[3]	Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis [J]. Nat Rev Cancer, 2013, 13(7): 511-518.
[4]	Marsh T, Pietras K, Mcallister SS. Fibroblasts as architects of cancer pathogenesis [J]. Biochim Biophys Acta, 2013, 1832(7): 1070-1078.
[5]	Gao P, Song YX, Wang ZN, et al. Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveillance, epidemiology, and end results (SEER) database [J]. BMC Cancer, 2013, 13: 123.
[6]	Galon J, Fox BA, Bifulco CB, et al.Immunoscore and immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 [J]. J Transl Med, 2016, 14: 273.
[7]	Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers [J]. J Natl Cancer Inst, 2010, 102(3): 193-201.
[8]	Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer [J]. Cancer Res, 1998, 58(16): 3491-3494.
[9]	Koch M, Beckhove P, Op Den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ [J]. Ann Surg, 2006, 244(6): 986-992; discussion 992-983.
[10]	Trabelsi M, Farah F, Zouari B, et al. An immunoscore system based on CD3(+) and CD8(+) infiltrating lymphocytes densities to predict the outcome of patients with colorectal adenocarcinoma [J]. Onco Targets Ther, 2019, 12: 8663-8673.
[11]	Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology [J]. Nat Rev Clin Oncol, 2017, 14(7): 399-416.
[12]	Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature [J]. PLoS One, 2012, 7(12): e50946.
[13]	Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer [J]. PLoS One, 2012, 7(10): e47045.
[14]	Schulz M, Salamero-Boix A, Niesel K, et al. Microenvironmental regulation of tumor progression and therapeutic Response in Brain Metastasis [J]. Front Immunol, 2019, 10: 1713.
[15]	Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? [J]. Pathol Int, 2016, 66(9): 491-505.
[16]	Malesci A, Bianchi P, Celesti G, et al. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage Ⅲ colorectal cancer [J]. Oncoimmunology, 2017, 6(12): e1342918.
[17]	Pinto ML, Rios E, Duraes C, et al. The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer [J]. Front Immunol, 2019, 10: 1875.
[18]	Zhang L, Zhao Y, Dai Y, et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location [J]. Front Immunol, 2018, 9: 1578.
[19]	Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers [J]. Oncotarget, 2017, 8(49): 86356-86368.
[20]	Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression [J]. Nature, 2004, 432(7015): 332-337.
[21]	Alexander J, Cukierman E. Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions [J]. Curr Opin Cell Biol, 2016, 42: 80-93.
[22]	Valkenburg KC, De Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy [J]. Nat Rev Clin Oncol, 2018, 15(6): 366-381.
[23]	Choi YJ, Kim HS, Park SH, et al. Phase II study of dovitinib in patients with castration-resistant prostate cancer(KCSG-GU11-05) [J]. Cancer Res Treat, 2018, 50(4): 1252-1259.
[24]	Mo F, Lin D, Takhar M, et al. Stromal gene expression is predictive for metastatic primary prostate cancer [J]. Eur Urol, 2018, 73(4): 524-532.
[25]	Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage [J]. Cell Oncol, 2007, 29(5): 387-398.
[26]	Park JH, Richards CH, Mcmillan DC, et al. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer [J]. Ann Oncol, 2014, 25(3): 644-651.
[27]	Fu M, Chen D, Luo F, et al. Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer [J]. Br J Cancer, 2020, 122: 388-396.
[28]	Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018 [J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.
[29]	Pang Y, Kartsonaki C, Guo Y, et al. Adiposity and risks of colorectal and small intestine cancer in Chinese adults: a prospective study of 0.5 million people [J]. Br J Cancer, 2018, 119(2): 248-250.
[30]	Eriksen AC, Sorensen FB, Lindebjerg J, et al. The prognostic value of tumour stroma ratio and tumor budding in stage II colon cancer. A nationwide population-based study [J]. Int J Colorectal Dis, 2018, 33(8): 1115-1124.
[31]	Sickert D, Aust DE, Langer S, et al. Characterization of macrophage subpopulations in colon cancer using tissue microarrays [J]. Histopathology, 2005, 46(5): 515-521.
[32]	Feng Q, Chang W, Mao Y, et al. Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage ii colon cancer [J]. Clin Cancer Res, 2019, 25(13): 3896-3907.
[33]	Oliphant R, Nicholson GA, Horgan PG, et al. Contribution of surgical specialization to improved colorectal cancer survival [J].Br J Surg, 2013, 100(10): 1388-1395.
[34]	Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer [J]. Ann Surg Oncol, 2012, 19(12): 3706-3712.

细胞类型	细胞亚型	浸润位置	预后
TILs	CD3^＋，CD4^＋，CD8^＋，CD45RO^＋	TC	DFS，OS
	CD3^＋	IM	OS
	CD4^＋，CD8^＋，FOXP3	TC	OS
	CD8^＋	TC	DFS
	CD8^＋，CD45RO^＋，FOXP3	IM	OS
	CD3^＋，CD8^＋，CD45RO^＋，FOXP3	IM	CSS
TAMs	CD163^＋	IM，ANM	OS
	CD80^＋	ANM	DFS
	CD68^＋	ANM	OS
	CD80^＋，CD163^＋	ANM	OS
	CD206^＋，CD68^＋	TC	DFS，OS

细胞类型	细胞亚型	浸润位置	预后
TILs	CD3^＋，CD4^＋，CD8^＋，CD45RO^＋	TC	DFS，OS
	CD3^＋	IM	OS
	CD4^＋，CD8^＋，FOXP3	TC	OS
	CD8^＋	TC	DFS
	CD8^＋，CD45RO^＋，FOXP3	IM	OS
	CD3^＋，CD8^＋，CD45RO^＋，FOXP3	IM	CSS
TAMs	CD163^＋	IM，ANM	OS
	CD80^＋	ANM	DFS
	CD68^＋	ANM	OS
	CD80^＋，CD163^＋	ANM	OS
	CD206^＋，CD68^＋	TC	DFS，OS

Please choose a citation manager

Content to export